The role of a novel antibacterial substance, cyclic opine-producing <i>Lacticaseibacillus rhamnosus</i> LS8 in ameliorating ulcerative colitis: A fecal microbiota transplantation study

Intestinal microbiota imbalance may worsen the progression of ulcerative colitis (UC). Lacticaseibacillus rhamnosus LS8 (LR) has potential ability to regulate through producing a novel antibacterial substance, cyclic opine: cycloalanopine. This study aimed investigate whether LR could ameliorate dextran sulfate sodium-induced UC in mice via modulating intestinal using fecal transplantation (FMT) experiment. The results showed that both and FMT attenuated as evidenced by (1) alleviating disease activity index colonic pathology; (2) up-regulating MUCs tight junction proteins; (3) increasing oxidative mediators decreasing antioxidant mediators; (4) down-regulating proinflammatory cytokines chemokines. These were mainly attributable microbiota-regulating effect LR, including beneficial bacteria (like Akkermansia) its related SCFAs, while harmful Proteobacteria) LPS, thereby suppressing hyperactivation TLR4/NF-κB. Consequently, can alleviate is dietary supplement attenuate UC.